AstraZeneca PLC - American Depositary Shares (NY:AZN)

158.82 -2.65 (-1.64%)

Delayed Quote Updated: 11:58 AM EDT, Oct 1, 2026 Add to My Watchlist

Price and Volume

Volume	1,359,169
Open	160.77
Bid (Size)	158.72 (100)
Ask (Size)	158.93 (100)
Prev. Close	161.47
Today's Range	158.51 - 161.32
52wk Range	153.41 - 212.71
Shares Outstanding	N/A
Dividend Yield	0.59%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. ↗

September 28, 2026

Wall Street expects an even bigger rebound for this beaten-down biotech stock.

Via The Motley Fool

Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer

September 25, 2026

From AstraZeneca

Via Business Wire

Performance

YTD	-15.7%	-15.7%
1 Month	-2.0%	-2.0%
3 Month	-13.6%	-13.6%
6 Month	-20.9%	-20.9%
1 Year	-15.7%	-15.7%

More News

Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture ↗

September 15, 2026

Via The Motley Fool

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

September 13, 2026

From AstraZeneca

Via Business Wire

TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

September 13, 2026

From AstraZeneca

Via Business Wire

AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears ↗

September 13, 2026

Via MarketBeat

IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer

September 08, 2026

From AstraZeneca

Via Business Wire

Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials

September 08, 2026

From AstraZeneca

Via Business Wire

ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer

September 04, 2026

From AstraZeneca

Via Business Wire

Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone ↗

September 03, 2026

Via The Motley Fool

AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer

September 01, 2026

From AstraZeneca

Via Business Wire

Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors ↗

August 29, 2026

Via The Motley Fool

TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints

August 27, 2026

From AstraZeneca

Via Business Wire

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity

August 26, 2026

Via FinancialNewsMedia

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity

August 26, 2026

From MarketNewsUpdates.com

Via GlobeNewswire

Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.

August 19, 2026

From USA News Group

Via GlobeNewswire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

August 17, 2026

From AstraZeneca

Via Business Wire

TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO

August 17, 2026

From AstraZeneca

Via Business Wire

Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗

August 16, 2026

Via The Motley Fool

Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen? ↗

August 13, 2026

Via The Motley Fool

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

August 04, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

July 28, 2026

From Pomerantz LLP

Via GlobeNewswire

Astrazeneca Q2 Earnings Call Highlights ↗

July 27, 2026

Via MarketBeat

Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers

July 27, 2026

From AstraZeneca

Via Business Wire

AstraZeneca results: H1 and Q2 2026

July 27, 2026

From AstraZeneca

Via Business Wire

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?

Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.

What exchange does AstraZeneca PLC - American Depositary Shares trade on?

AstraZeneca PLC - American Depositary Shares trades on the New York Stock Exchange

What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?

The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the New York Stock Exchange

What is the current price of AstraZeneca PLC - American Depositary Shares?

The current price of AstraZeneca PLC - American Depositary Shares is 158.82

When was AstraZeneca PLC - American Depositary Shares last traded?

The last trade of AstraZeneca PLC - American Depositary Shares was at 10/01/26 11:58 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.